Celyad Oncology SA (EBR:CYAD)
Belgium · Delayed Price · Currency is EUR 0.2900
-0.0100 (-3.33%)
May 22, 2026, 5:28 PM CET
Celyad Oncology Company Description
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property.
Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies.
The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Celyad Oncology SA
| Country | Belgium |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Matthew Kane |
Contact Details
Address: Axis Business Park Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 1 039 41 00 |
| Website | celyad.com |
Stock Details
| Ticker Symbol | CYAD |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0974260896 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michel E. J. Lussier BME, M.B.A., M.S., MS BME | Co-Founder and Non-Executive Director |
| David Georges | Vice President of Finance and Administration |
| Sara Zelkovic | Communications and Investor Relations Director |
| An Phan | Head of Legal |
| Philippe Dechamps | Corporate Secretary |